Asahi Of Japan, NxStage Of U.S. In Pact To Market Dialysis Devices
This article was originally published in PharmAsia News
Executive Summary
Japan's Asahi Kasei Kuraray Medical and U.S.-based NxStage Medical have signed an exclusive licensing agreement for Asahi to produce and market NxStage devices in Asia. The pact also allows Asahi to market the devices in the rest of the world, but without exclusivity. The devices involved are disposable medical equipment used in home kidney dialysis. NxStage retained all rights to the equipment in North America. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.